Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.
Recent experimental evidence has shown that acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise from transformed immature hematopoietic cells following the accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells and committed progenitors. The series of transforming events initially gives rise to preleukemic stem cells (pre-LSC), preceding the formation of fully transformed leukemia stem cells (LSC). Despite the established use of poly-chemotherapy, relapse continues to be the most common cause of death in AML and MDS. The therapeutic elimination of all LSC, as well as pre-LSC, which provide a silent reservoir for the re-formation of LSC, will be essential for achieving lasting cures. Conventional sequencing and next-generation genome sequencing have allowed us to describe many of the recurrent mutations in the bulk cell populations in AML and MDS, and recent work has also focused on identifying the initial molecular changes contributing to leukemogenesis. Here we review recent and ongoing advances in understanding the roles of pre-LSC, and the aberrations that lead to pre-LSC formation and subsequent LSC transformation.
Department of Cell Biology, Albert Einstein College of Medicine, New York, New York, USA.
Ashley
A
Pandolfi
Laura
L
Barreyro
Ulrich
U
Steidl
D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000473:pathology*; D008967:Molecular Biology; D014411:Neoplastic Stem Cells / Q000473:pathology* / Q000502:physiology; D011289:Preleukemia / Q000235:genetics / Q000473:pathology*